Lilly Foundayo (orforglipron) Approved as First Non-Peptide GLP-1 Weight-Loss Pill

FDA approved Lilly's Foundayo on 4/1 for chronic weight management. As the first non-peptide GLP-1 receptor agonist oral formulation, it eliminates meal and water restrictions. CNPV priority review determined the action in 50 days.